Pacira BioSciences stock
PCRXNASDAQPacira BioSciences, Inc., HealthcareISIN US6951271005
58Score 58 out of 100, Neutral
Price and trend
82 / 100
Price history
+53% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 43% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is at its 52-week high. Largest decline in 16 years: 90% (February 2015 to August 2024).
Chart figures for advanced users
- SMA 50$30.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.16
- The lowest closing price of the last twelve months.
- Resistance$36.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pacira BioSciences, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $1.46B, is number 59 of 77 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $754.33M (up 3.8%) and adjusted earnings per share of $2.90 (up 10.1%).
- MEQIRI Score 58 out of 100 (Neutral): rank 299 of 702 in Healthcare, median 53.
Show more
- The P/E is 39.5 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 63.3).
- Our model puts fair value at $46.49, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 448% of earnings over the last 12 months.Fundamentals 58
- Analysts expect strong earnings growthUp 15.9% a year through 2027 (estimates from 5 analysts).Growth 55
Weaknesses
- Earnings per share fallingDown 45.8% a year since 2020.Growth 55
- Margin fallingOperating margin 4.6%, average of the prior years 10.8% (to 2024).Profitability 39
- Interest barely coveredOperating profit covers interest only 2.2 times.Stability 60
Its standout strengths are momentum and technical analysis, while capital allocation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $33.21 and expensive above $77.48 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $75.49 (cash-flow model) and $17.48 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $40.14, at 7.8% it would be $56.01.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.7% on the twelve months before. Revenue has grown strongly since 2008, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating 5%, net 1%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 5 Nov 2026EPS reported $0.72 (expected $0.75)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.900.0%
- Revenue
- $754.33M0.0%
- Earnings per share
- $3.460.0%
- Revenue
- $790.02M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −7.6%2026 guidance ranges were updated for the Zimmer transaction closing; the EXPAREL guidance was kept despite a softer second quarter.
“That brings us to our full year guidance for 2026, where we are updating the following ranges to adjust for the closing of the Zimmer transaction.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $660,710 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Riker LaurenSale
8 Oct 2026, Senior Vice President, Finance
- Shares
- 6,000
- Price
- $36.32
- Value
- $217,920
- Slonin JonathanSale
17 Aug 2026, Chief Medical Officer
- Shares
- 3,040
- Price
- $23.23
- Value
- $70,619
- Riker LaurenSale
11 Jun 2026, Senior Vice President, Finance
- Shares
- 6,115
- Price
- $23.50
- Value
- $143,703
Show 1 more
- Williams KristenSale
4 Jun 2026, Chief Administrative Officer
- Shares
- 10,259
- Price
- $22.27
- Value
- $228,468
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pacira BioSciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- SupernusSUPN $1.7B62
- AlvotechALVO $1.67B42
- ANI PharmaceuticalsANIP $1.63B61
- PolyPeptide GroupPPGN.SW $1.6B42
- Phibro Animal HealthPAHC $1.44B57
- Cronos GroupCRON $1.25B61
- BioGaiaBIOG-B.ST $1.24B77
- Amphastar PharmaceuticalsAMPH $1.23B75
ETFs that hold Pacira BioSciences
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.12% | 0.39% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.25B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.08% | 0.30% | €2.31B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €964.08M |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.02% | 0.39% | €190.04M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.